ASCO 2022 Post-conference overview
ASCO 2022 Post-conference overview
20 PagesThis post-conference overview of ASCO 2022 highlights major advances in oncology across lung cancer, breast cancer, and acute myeloid leukemia (AML). In breast cancer, the Phase 3 DESTINY-Breast04 study emerged as one of the most significant presentations, demonstrating the potential of antibody-drug conjugates (ADCs) to improve treatment outcomes in metastatic breast cancer. Sacituzumab govitecan also gained attention through positive results from the TROPiCS-02 and ASCENT studies, showing meaningful clinical benefits in advanced breast cancer subtypes. Several presentations emphasized biomarker-driven treatment approaches, including research on alpelisib for patients with PIK3CA-mutated disease. Across all three cancer areas, the conference showcased growing interest in novel mechanisms
